Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HRMY Stock Forecast 2026-2027
$32.20
Current Price
$1.86B
Market Cap
Buy 6
Hold 4
Sell 1
Wall St Analyst Ratings
Distance to HRMY Price Targets
+164.0%
To High Target of $85.00
+33.5%
To Median Target of $43.00
-13.0%
To Low Target of $28.00
HRMY Price Momentum
+1.9%
1 Week Change
-1.8%
1 Month Change
-9.6%
1 Year Change
-13.9%
Year-to-Date Change
-21.2%
From 52W High of $40.87
+26.2%
From 52W Low of $25.52
📊 TOP ANALYST CALLS
Did HRMY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Harmony Biosciences is one of their latest high-conviction picks.
Latest HRMY Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, HRMY has a bullish consensus with a median price target of $43.00 (ranging from $28.00 to $85.00). The overall analyst rating is Buy (7.6/10). Currently trading at $32.20, the median forecast implies a 33.5% upside. This outlook is supported by 6 Buy, 4 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HRMY Analyst Ratings
6
Buy
4
Hold
1
Sell
HRMY Price Target Range
Low
$28.00
Average
$43.00
High
$85.00
Current: $32.20
Latest HRMY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HRMY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 8, 2026 | Truist Securities | Danielle Brill | Hold | Maintains | $29.00 |
| Feb 25, 2026 | UBS | Neutral | Maintains | $N/A | |
| Feb 25, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 25, 2026 | B of A Securities | Underperform | Maintains | $N/A | |
| Feb 25, 2026 | Needham | Buy | Maintains | $N/A | |
| Feb 11, 2026 | UBS | Neutral | Downgrade | $N/A | |
| Jan 8, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Dec 1, 2025 | Mizuho | Outperform | Maintains | $N/A | |
| Nov 24, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 24, 2025 | Needham | Buy | Reiterates | $N/A | |
| Nov 6, 2025 | Mizuho | Outperform | Maintains | $N/A | |
| Oct 15, 2025 | UBS | Buy | Maintains | $N/A | |
| Sep 25, 2025 | Mizuho | Outperform | Maintains | $N/A | |
| Sep 25, 2025 | Deutsche Bank | Buy | Maintains | $N/A | |
| Sep 25, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 24, 2025 | Needham | Buy | Maintains | $N/A | |
| Jul 21, 2025 | Truist Securities | Buy | Initiates | $N/A | |
| Jul 10, 2025 | Deutsche Bank | Buy | Maintains | $N/A | |
| Jun 2, 2025 | Oppenheimer | Andreas Argyrides | Outperform | Assumes | $61.00 |
| May 15, 2025 | Mizuho | Outperform | Maintains | $N/A |
Harmony Biosciences Holdings, Inc. (HRMY) Competitors
The following stocks are similar to Harmony Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
HRMY
Harmony Biosciences
mkt cap
1.83B
Harmony Biosciences Holdings, Inc. (HRMY) Financial Data
Harmony Biosciences Holdings, Inc. has a market capitalization of $1.86B with a P/E ratio of 13.3x. The company generates $899.11M in trailing twelve-month revenue with a 16.2% profit margin.
Revenue growth is +16.6% quarter-over-quarter, while maintaining an operating margin of +17.3% and return on equity of +17.9%.
Valuation Metrics
Market Cap
$1.86B
Enterprise Value
$1.43B
P/E Ratio
13.3x
PEG Ratio
-0.5x
Price/Sales
2.1x
Growth & Margins
Revenue Growth (YoY)
+16.6%
Gross Margin
+79.3%
Operating Margin
+17.3%
Net Margin
+16.2%
EPS Growth
-28.7%
Financial Health
Cash/Price Ratio
+34.4%
Current Ratio
3.6x
Debt/Equity
18.1x
ROE
+17.9%
ROA
+10.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Harmony Biosciences Holdings, Inc. (HRMY) Business Model
About Harmony Biosciences Holdings, Inc.
What They Do
Develops therapies for neurological disorders.
Business Model
The company generates revenue primarily through the commercialization of its lead product, WAKIX, which is designed to treat narcolepsy and cataplexy. By focusing on innovative pharmacotherapies for neurological conditions, Harmony Biosciences targets underserved markets with significant unmet medical needs, allowing it to capture a niche segment of the pharmaceutical market.
Additional Information
Founded in 2017 and based in Plymouth Meeting, Pennsylvania, Harmony Biosciences has received approval for expanded indications of WAKIX, including treatments for pediatric patients. The company is committed to advancing solutions for rare and debilitating neurological diseases, positioning itself as a key player in the health technology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
293
CEO
Dr. Jeffrey M. Dayno M.D.
Country
United States
IPO Year
2020
Website
www.harmonybiosciences.comHarmony Biosciences Holdings, Inc. (HRMY) Latest News & Analysis
Latest News
Quick Summary
Harmony Biosciences will participate in the Goldman Sachs Healthcare Conference on June 9, 2026, and the Oppenheimer CNS Summit on June 10, 2026, with webcasts available.
Why It Matters
Harmony Biosciences' participation in key investor conferences highlights its visibility and engagement in the healthcare sector, potentially influencing investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Harmony Biosciences Holdings, Inc. (HRMY) held its Q1 2026 earnings call, providing updates on financial performance and business developments. Details on earnings will be available in the transcript.
Why It Matters
The Q1 2026 earnings call provides insights into Harmony Biosciences' financial performance and future prospects, influencing stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Harmony Biosciences reported Q1 2026 revenue of $215.4 million, a 17% increase year-over-year for WAKIX®. Despite market access challenges, the company reaffirmed its full-year revenue guidance.
Why It Matters
Harmony Biosciences' strong Q1 2026 revenue and continued demand for WAKIX highlight growth potential, despite market access challenges. Reinforced revenue guidance may bolster investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Harmony Biosciences (HRMY) reported Q3 earnings of $0.55 per share, below the Zacks estimate of $0.76 and down from $0.78 per share year-over-year.
Why It Matters
Harmony Biosciences' earnings miss signals potential operational issues and decreased profitability, likely affecting stock performance and investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Wall Street Analysts Think Harmony Biosciences (HRMY) Could Surge 34.81%: Read This Before Placing a Bet
1 month ago
Quick Summary
Analysts' price targets for Harmony Biosciences (HRMY) suggest a 34.8% upside, supported by consensus on increased earnings estimates.
Why It Matters
Analysts predict a 34.8% upside for Harmony Biosciences, suggesting potential growth. Increased earnings estimates indicate positive sentiment, influencing investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Harmony Biosciences (HRMY) is expected to outperform the market due to its above-average growth in financial performance.
Why It Matters
Harmony Biosciences’ strong financial growth potential signals a favorable investment opportunity, likely attracting interest and driving stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About HRMY Stock
What is Harmony Biosciences Holdings, Inc.'s (HRMY) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Harmony Biosciences Holdings, Inc. (HRMY) has a median price target of $43.00. The highest price target is $85.00 and the lowest is $28.00.
Is HRMY stock a good investment in 2026?
According to current analyst ratings, HRMY has 6 Buy ratings, 4 Hold ratings, and 1 Sell ratings. The stock is currently trading at $32.20. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HRMY stock?
Wall Street analysts predict HRMY stock could reach $43.00 in the next 12 months. This represents a 33.5% increase from the current price of $32.20. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Harmony Biosciences Holdings, Inc.'s business model?
The company generates revenue primarily through the commercialization of its lead product, WAKIX, which is designed to treat narcolepsy and cataplexy. By focusing on innovative pharmacotherapies for neurological conditions, Harmony Biosciences targets underserved markets with significant unmet medical needs, allowing it to capture a niche segment of the pharmaceutical market.
What is the highest forecasted price for HRMY Harmony Biosciences Holdings, Inc.?
The highest price target for HRMY is $85.00 from at , which represents a 164.0% increase from the current price of $32.20.
What is the lowest forecasted price for HRMY Harmony Biosciences Holdings, Inc.?
The lowest price target for HRMY is $28.00 from at , which represents a -13.0% decrease from the current price of $32.20.
What is the overall HRMY consensus from analysts for Harmony Biosciences Holdings, Inc.?
The overall analyst consensus for HRMY is bullish. Out of 3 Wall Street analysts, 6 rate it as Buy, 4 as Hold, and 1 as Sell, with a median price target of $43.00.
How accurate are HRMY stock price projections?
Stock price projections, including those for Harmony Biosciences Holdings, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 6:15 AM UTC